trending Market Intelligence /marketintelligence/en/news-insights/trending/zkleyCAOLX3J6zwXJ_BNbg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

ProQR Therapeutics closes $57.5M shares offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


ProQR Therapeutics closes $57.5M shares offering

ProQR Therapeutics NV closed a public offering of ordinary shares raising about $57.5 million in gross proceeds.

The Leiden, Netherlands-based biopharmaceutical company sold 10,454,545 ordinary shares at $5.5 apiece. This includes 1,363,636 additional shares sold as underwriters fully exercised the overallotment option.

The company previously said it plans to use net proceeds from the offering to fund ongoing research and development activities, for working capital and for other general corporate purposes.

The Dutch biopharmaceutical company develops treatments for genetic disorders.

Citigroup Global Markets and Evercore ISI were joint book-runners for the offering, while Cantor Fitzgerald & Co. and JMP Securities were lead managers. Chardan and Kempen were co-managers.